Xenetic Biosciences’ (XBIO) “Neutral” Rating Reiterated at HC Wainwright

Xenetic Biosciences (NASDAQ:XBIO)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports.

Xenetic Biosciences Trading Up 3.5 %

Shares of XBIO traded up $0.12 during trading hours on Thursday, reaching $3.64. 1,641 shares of the stock traded hands, compared to its average volume of 12,689. The stock has a fifty day simple moving average of $4.00 and a 200 day simple moving average of $4.00. Xenetic Biosciences has a 52 week low of $2.78 and a 52 week high of $5.20. The company has a market cap of $5.62 million, a price-to-earnings ratio of -1.37 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million. Analysts predict that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC boosted its stake in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,550 shares of the company’s stock after acquiring an additional 9,700 shares during the period. Renaissance Technologies LLC owned 1.66% of Xenetic Biosciences worth $102,000 as of its most recent filing with the SEC. 15.12% of the stock is currently owned by hedge funds and other institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.